Cytokinetics’s Buy Rating Reaffirmed at Roth Capital (CYTK)
Shares of Cytokinetics (NASDAQ:CYTK) traded down 1.61% on Thursday, hitting $4.29. 641,243 shares of the company’s stock traded hands. Cytokinetics has a 52 week low of $3.96 and a 52 week high of $14.28. The stock’s 50-day moving average is $4.81 and its 200-day moving average is $7.38. The company’s market cap is $157.0 million.
Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.34) by $0.07. The company had revenue of $8.00 million for the quarter, compared to the consensus estimate of $7.69 million. Analysts expect that Cytokinetics will post $-1.16 EPS for the current fiscal year.
CYTK has been the subject of a number of other recent research reports. Analysts at Leerink Swann reiterated an “outperform” rating on shares of Cytokinetics in a research note on Monday, May 19th. They now have a $8.00 price target on the stock, down previously from $20.00. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Cytokinetics in a research note on Thursday, May 8th. They now have a $8.00 price target on the stock, down previously from $9.00. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Cytokinetics in a research note on Monday, April 28th. They now have a $9.00 price target on the stock, down previously from $22.00. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $8.05.
Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.